Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Stock Chart & Stats
$13.15
-$0.83(-1.65%)
At close: 4:00 PM EST
$13.15
-$0.83(-1.65%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume45.38K
Average Volume (3M)2.79M
Market Cap
$938.56M
Enterprise Value$151.89M
Total Cash (Recent Filing)$380.48M
Total Debt (Recent Filing)$75.73M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Feb 26, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding70,847,404
10 Day Avg. Volume2,107,569
30 Day Avg. Volume2,788,461
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)7.62
Price to Sales (P/S)0.00
P/FCF Ratio-29.07
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-102.15
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$15.38Price Target Upside16.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-3.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMoonLake presented positive results from the open-label Phase II LEDA study evaluating 120mg sonelokimab in 32 moderate-to-severe PPP patients.
Financial PositionThe balance sheet along with funds from the non-dilutive financing agreement with Hercules Capital are expected to fund operations into H2 2027.
Regulatory ApprovalThere is optimism for a viable path to licensure, encouraged by the timely engagement with regulators.
Bears Say
Clinical Trial OutcomesIn September, the company announced disappointing results from the Phase III VELA program with only one trial hitting statistical significance on the primary endpoint of HiSCR75.
Market PenetrationThe market penetration will likely be significantly lower than previous projection.
Stock ValuationThe current valuation of MoonLake Immunotherapeutics, implying a less than $300M enterprise value, is deemed inappropriate by analysts.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $938.56M.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 92 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Nov 05, 2025. The company reported -$1.1 earnings per share for the quarter, missing the consensus estimate of -$0.879 by -$0.221.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.98.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 70,847,404 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$1.1 in its last earnings report, missing expectations of -$0.879. Following the earnings report the stock price went up 4.541%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
MoonLake Immunotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.38 (16.96% Upside)
$15.38 (16.96% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 249.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $46.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.79%
12-Months-Change
Fundamentals
Return on Equity
-54.17%
Trailing 12-Months
Asset Growth
-20.05%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) is a biotechnology company focused on developing innovative therapies for inflammatory diseases. The company leverages its proprietary nanobody technology to create targeted, potent, and effective treatments aimed at improving patient outcomes. MoonLake's core products include a pipeline of therapeutic candidates designed to address conditions such as dermatological, rheumatological, and gastroenterological diseases.
MLTX Stock 12 Month Forecast
Average Price Target
$15.38
▲(16.96% Upside)
Technical Analysis
Protagonist Therapeutics
―
Zai Lab
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
Ownership Overview
40.33% Insiders
14.20% Mutual Funds
41.83% Other Institutional Investors
3.08% Public Companies and Individual Investors